nirmatrelvir plus ritonavir; placebo; article; coronavirus disease 2019; COVID-19 testing; drug efficacy; health care personnel; human; marketing authorization; Medicines and Healthcare products Regulatory Agency; patient safety; pharmacovigilance; polymerase chain reaction; rebound; risk benefit analysis; Severe acute respiratory syndrome coronavirus 2; side effect; United Kingdom; viral clearance; virus load; virus resistance; Yellow Card report; paxlovid